Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
PROGESTERONE
Serono Limited
4 %w/w
Vaginal Gel
1997-07-25
PART II SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Crinone 4% w/w progesterone vaginal gel 2 QUALITATIVE AND QUANTITATIVE COMPOSITION For excipients see section 6.1. 3 PHARMACEUTICAL FORM Vaginal gel White to off white gel contained within a white plastic applicator. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Menopausal disposal (in combination with oestrogen therapy). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION INTRAVAGINAL APPLICATION. Treatment of menopausal disorders: One application (1.125g 4% gel) every other day for the last 12 days of each oestrogenic sequence. Children: not applicable. 4.3 CONTRAINDICATIONS Crinone should not be used in individuals with any of the following conditions: 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE Crinone 4% Progesterone Vaginal Gel can be prescribed with an oestrogen product as HRT. Epidemiological evidence suggests that the use of HRT is associated with an increased risk of developing deep vein thrombosis (DVT) or pulmonary embolism. The use of Crinone in combination with oestrogen therapy as HRT was not included in these Active Ingredient 4% gel Mg/dose % w/w Progesterone 45 4.0 1. Known sensitivity to Crinone (progesterone or any of the other ingredients). 2. Undiagnosed vaginal bleeding. 3. Known or suspected malignancy of the breast or genital organs. 4. Acute porphyria. 5. Thrombophlebitis, thromboembolic disorder, cerebral apoplexy, or patients with a history of these conditions. IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 30/01/2007_ _CRN 2032969_ _page number: 1_ studies. However, when Crinone is co-prescribed as HRT the prescribing information for the oestrogen product should be referred to. In cases of breakthrough bleed Read the complete document